Fesharaki Shirin Alsadat Hashemi, Abari Sara Kiani, Yazdani Behnaz, Farajollahi Hadi, Kalashami Fatemeh Padidari, Zadsar Anahita, Sirous Hajar
Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, I.R. Iran.
Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, I.R. Iran.
Res Pharm Sci. 2025 Jun 17;20(3):356-372. doi: 10.4103/RPS.RPS_209_23. eCollection 2025 Jun.
One of the most prevalent types of malignancies affecting the cells in the mucosal surface of the oral cavity and pharynx regions is head and neck squamous cell carcinoma (HNSCC). This study analyzed the metabolic profile of genes involved in the metabolism of fatty acids (FAs) to identify biomarkers with prognostic and diagnostic potential in HNSCC.
Gene set enrichment analysis, differential gene expression, and correlation analysis methods were used to examine the enrichment and expression patterns of genes involved in the metabolism of FAs in the HNSCC tissue samples. Gene ontology and network analysis were performed to explore the molecular interactions in the metabolic pathways of FAs. The diagnostic and prognostic potentials of identified highly dysregulated genes in HNSCC were examined by ROC test and Cox-regression methods.
FINDINGS/RESULTS: FA-associated metabolic pathways were significantly dysregulated in the HNSC cancer samples. For the diagnosis of HNSC cancer, CYP4B1 and FMO2 could be potential biomarkers, while for the prognosis of HNSCC survival periods, ACOX2, CYP4F12, and ELOVL6 could hold valuable biomarker potential.
The findings could help target the metabolism of FAs using the identified biomarkers for the design of new therapeutic opportunities for patients with HNSCC.
影响口腔和咽区域黏膜表面细胞的最常见恶性肿瘤类型之一是头颈部鳞状细胞癌(HNSCC)。本研究分析了参与脂肪酸(FAs)代谢的基因的代谢谱,以鉴定HNSCC中具有预后和诊断潜力的生物标志物。
采用基因集富集分析、差异基因表达分析和相关性分析方法,研究HNSCC组织样本中参与FAs代谢的基因的富集和表达模式。进行基因本体论和网络分析,以探索FAs代谢途径中的分子相互作用。通过ROC检验和Cox回归方法检测HNSCC中鉴定出的高度失调基因的诊断和预后潜力。
FA相关代谢途径在HNSC癌样本中显著失调。对于HNSC癌的诊断,CYP4B1和FMO2可能是潜在的生物标志物,而对于HNSCC生存期的预后,ACOX2、CYP4F12和ELOVL6可能具有有价值的生物标志物潜力。
这些发现有助于利用鉴定出的生物标志物靶向FAs代谢,为HNSCC患者设计新的治疗机会。